Pyridine

Pyridine

SCHEMBL3467693

CC(C)=O.c1ccncc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 4/20 0.60
TSHR P16473 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
KMT2A Q03164 2/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 4/20 0.39
APP P05067 1/20 0.39
GAA P10253 1/20 0.39
HCAR3 P49019 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
FFAR3 O14843 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
TAAR1 Q96RJ0 1/20 0.36
PLOD2 O00469 1/20 0.36
PLOD3 O60568 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL2064519 0.97 NAPRT (0.56) NAPRTTSHRTDP1KMT2ALMNA
Benzene SCHEMBL27338905 0.97 NAPRT (0.56) NAPRTTSHRTDP1KMT2ALMNA
Pyridine SCHEMBL10902375 0.97 NAPRT (0.56) NAPRTTSHRTDP1KMT2ALMNA
Pyridine SCHEMBL28199527 0.97 NAPRT (0.56) NAPRTTSHRTDP1KMT2ALMNA
Pyridine SCHEMBL9073450 0.97 NAPRT (0.56) NAPRTTSHRTDP1KMT2ALMNA
Pyridine SCHEMBL27629427 0.97 NAPRT (0.56) NAPRTTSHRTDP1KMT2ALMNA
Pyridine SCHEMBL4216849 0.97 NAPRT (0.56) NAPRTTSHRTDP1KMT2ALMNA
Pyridine SCHEMBL10977701 0.93 NAPRT (0.60) NAPRTTSHRTDP1KMT2ALMNA
Pyridine SCHEMBL179840 0.93 NAPRT (0.60) NAPRTTSHRTDP1KMT2ALMNA
Pyridine SCHEMBL11125163 0.93 NAPRT (0.60) NAPRTTSHRTDP1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104645966-A Preparation of Tb<3-x>PrxTaO7-zeolite molecular sieve composite porous nanometer catalyst material and application thereof NANJING UNIVERSITY OF TECHNOLOGY 2015-05-27 CN claimed
CN-104293859-A Enzymatic synthesis method of galactose ligand molecule CHENG YI 2015-01-21 CN claimed
CN-102040511-A Method for preparing rupestonic aid NANJING SORUN HERBAL TECH DEV 2011-05-04 CN claimed
CN-101463383-A Sterilizing gas rapid detection reagent label YI QU (CN) 2009-06-24 CN claimed
EP-0906417-B1 CROSS-LINKED PROTEIN CRYSTAL FORMULATIONS AND THEIR USE AS CATALYSTS IN ORGANIC SOLVENTS ALTUS PHARMACEUTICALS INC (US) 2008-04-23 EP claimed
US-7053055-B2 Compounds of unstable DP IV-inhibitors PROSIDION LTD. (GB) 2006-05-30 US claimed
US-20010020006-A1 Compounds of unstable DP IV-inhibitors PROSIDION LIMITED (GB) 2001-09-06 US claimed
CN-1094618-A A kind of method of from poultry blood, extracting haemachrome and protein powder LIN YIZHEN (CN) 1994-11-09 CN claimed
US-11742151-B2 Aerosol assisted chemical vapor deposition methods useful for making dye-sensitized solar cells with platinum dialkyldithiocarbamate complexes KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2023-08-29 US disclosed
US-20200381186-A1 PLATINUM COMPOUNDS AND METHODS USEFUL FOR MAKING DYE-SENSITIZED SOLAR CELLS KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2020-12-03 US disclosed
EP-3644990-A1 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR Merck Sharp & Dohme Corp. (US) 2020-05-06 EP disclosed
US-20200109137-A1 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR MERCK SHARP & DOHME CORP. (US) 2020-04-09 US disclosed
CN-107474208-B A kind of multi-functional benzoxazine composite material and preparation method 四川天策聚材科技有限公司 2019-10-22 CN disclosed
CN-110294785-A A kind of steroidal ring expansion compound and preparation method thereof 天津药业研究院有限公司 2019-10-01 CN disclosed
US-4732933-A HALF-ESTERIFIED MALEIC ANHYDRIDE-STYRENE COPOLYMER KAYAKU ANTIBIOTICS RESEARCH CO., LTD. (JP) 1988-03-22 US disclosed
EP-0099091-B1 HEXAHYDRODIOXOPYRIMIDINES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1986-10-29 EP disclosed
US-4536504-A ANTITUMOR, ANTIVIRAL, AND ANTIBACTERIAL AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1985-08-20 US disclosed
EP-0099091-A1 Hexahydrodioxopyrimidines, their production and use Takeda Chemical Industries, Ltd. (JP) 1984-01-25 EP disclosed
US-4426522-A ANTICOCCIDIAL ABIC LTD. (IL) 1984-01-17 US disclosed
EP-0058534-A2 Hexahydro-1,2,4-triazine-3,5-dione derivatives and their use as feed additives ABIC LTD. (IL) 1982-08-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109137-A1 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR CHRM5, CHRM4, CHRM3 NAPRT 1334/4885TSHR 153/4885TDP1 1603/4885
US-20010020006-A1 Compounds of unstable DP IV-inhibitors DPP4, DPP3, SLC2A4 NAPRT 2131/4885TSHR 4726/4885TDP1 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.